Haleon plc (NYSE:HLN) Short Interest Update

Haleon plc (NYSE:HLN - Get Free Report) saw a significant decline in short interest in May. As of May 15th, there was short interest totalling 19,620,000 shares, a decline of 13.6% from the April 30th total of 22,720,000 shares. Currently, 0.4% of the shares of the company are short sold. Based on an average daily volume of 14,360,000 shares, the short-interest ratio is presently 1.4 days.

Haleon Price Performance

Shares of HLN stock traded down $0.05 during trading hours on Friday, hitting $11.07. The stock had a trading volume of 13,897,070 shares, compared to its average volume of 8,750,126. Haleon has a one year low of $8.25 and a one year high of $11.42. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The stock's 50-day moving average price is $10.50 and its two-hundred day moving average price is $10.03. The stock has a market capitalization of $49.84 billion, a price-to-earnings ratio of 32.56, a PEG ratio of 2.82 and a beta of 0.31.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Barclays restated an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. BNP Paribas Exane upgraded Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price objective on the stock in a research report on Tuesday, May 27th. Hsbc Global Res downgraded Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Wall Street Zen upgraded Haleon from a "hold" rating to a "buy" rating in a research report on Friday. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Haleon in a report on Monday, March 3rd. Five analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $12.33.

Institutional Investors Weigh In On Haleon

Several large investors have recently added to or reduced their stakes in HLN. Brighton Jones LLC bought a new stake in Haleon during the fourth quarter worth approximately $187,000. Caprock Group LLC increased its stake in Haleon by 13.8% during the fourth quarter. Caprock Group LLC now owns 43,566 shares of the company's stock worth $416,000 after acquiring an additional 5,299 shares during the last quarter. Spire Wealth Management bought a new stake in Haleon during the fourth quarter worth approximately $39,000. Golden State Equity Partners increased its stake in Haleon by 342.8% during the fourth quarter. Golden State Equity Partners now owns 16,633 shares of the company's stock worth $159,000 after acquiring an additional 12,877 shares during the last quarter. Finally, Greenleaf Trust increased its stake in Haleon by 8.4% during the fourth quarter. Greenleaf Trust now owns 17,225 shares of the company's stock worth $164,000 after acquiring an additional 1,333 shares during the last quarter. 6.67% of the stock is owned by institutional investors.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.